Financial Review: PROCEPT BioRobotics (PRCT) & Its Peers

PROCEPT BioRobotics (NASDAQ:PRCTGet Rating) is one of 219 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare PROCEPT BioRobotics to similar businesses based on the strength of its valuation, profitability, analyst recommendations, risk, earnings, dividends and institutional ownership.


This table compares PROCEPT BioRobotics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics -138.49% -26.41% -20.85%
PROCEPT BioRobotics Competitors -1,540.74% -61.47% -22.07%

Earnings & Valuation

This table compares PROCEPT BioRobotics and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
PROCEPT BioRobotics $34.47 million -$59.85 million -16.41
PROCEPT BioRobotics Competitors $1.15 billion $85.63 million -398.59

PROCEPT BioRobotics’ peers have higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and target prices for PROCEPT BioRobotics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics 0 1 7 0 2.88
PROCEPT BioRobotics Competitors 668 3099 7294 164 2.62

PROCEPT BioRobotics presently has a consensus target price of $43.50, indicating a potential upside of 7.75%. As a group, “Surgical & medical instruments” companies have a potential upside of 40.47%. Given PROCEPT BioRobotics’ peers higher probable upside, analysts clearly believe PROCEPT BioRobotics has less favorable growth aspects than its peers.

Institutional and Insider Ownership

76.2% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 48.3% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 40.8% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 14.6% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


PROCEPT BioRobotics beats its peers on 8 of the 12 factors compared.

About PROCEPT BioRobotics

(Get Rating)

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with's FREE daily email newsletter.